Detalles de la búsqueda
1.
Adverse outcomes in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: Follow-up of patients diagnosed 2002-2017 in a complete coverage and nationwide agnostic register study.
Am J Hematol
; 97(4): 421-430, 2022 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-35015312
2.
Successful tyrosine kinase inhibitor discontinuation outside clinical trials - data from the population-based Swedish chronic myeloid leukaemia registry.
Br J Haematol
; 193(5): 915-921, 2021 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-33782950
3.
Long-term tolerability and efficacy after initial PegIFN-α addition to dasatinib in CML-CP: Five-year follow-up of the NordCML007 study.
Eur J Haematol
; 107(6): 617-623, 2021 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-34418168
4.
Tyrosine kinase inhibitor usage, treatment outcome, and prognostic scores in CML: report from the population-based Swedish CML registry.
Blood
; 122(7): 1284-92, 2013 Aug 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-23843494
5.
Combination of pegylated IFN-α2b with imatinib increases molecular response rates in patients with low- or intermediate-risk chronic myeloid leukemia.
Blood
; 118(12): 3228-35, 2011 Sep 22.
Artículo
en Inglés
| MEDLINE | ID: mdl-21685374
6.
IFN-α with dasatinib broadens the immune repertoire in patients with chronic-phase chronic myeloid leukemia.
J Clin Invest
; 132(17)2022 09 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-36047494
7.
Molecular status 36 months after TKI discontinuation in CML is highly predictive for subsequent loss of MMR-final report from AFTER-SKI.
Leukemia
; 35(8): 2416-2418, 2021 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-33589755
8.
Impact of imiglucerase supply shortage on clinical and laboratory parameters in Norrbottnian patients with Gaucher disease type 3.
Arch Immunol Ther Exp (Warsz)
; 63(1): 65-71, 2015 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-25205209
Resultados
1 -
8
de 8
1
Próxima >
>>